BridgeMD
Prevention study for HIV Infections
Official title Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro
ClinicalTrials.gov ID: NCT07584122
What this study is testing
What is Oral Pre-Exposure Prophylaxis (PrEP) (Tenofovir Disoproxil Fumarate/Emtricitabine)?
Oral Pre-Exposure Prophylaxis (PrEP) (Tenofovir Disoproxil Fumarate/Emtricitabine) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for hiv infections.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to improve access to HIV prevention using pre-exposure prophylaxis (PrEP) among underserved populations in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. Despite the proven effectiveness of PrEP, many people at higher risk of HIV face barriers to accessing and continuing this prevention method, especially those living in socially and economically vulnerable communities.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 15 and older. Healthy volunteers may be eligible.
You may be able to join if
- Individuals aged 15 years or older
- Gay, bisexual, and other men who have sex with men (MSM)
- Transgender women and travestis
- Other sexual and gender minorities (SGM)
- Cisgender women in situations of social or economic vulnerability
You likely can't join if
- Positive HIV test result at screening or during study participation
- Individuals not eligible for PrEP according to Brazilian national guidelines
See the full eligibility criteria
- Individuals aged 15 years or older
- Gay, bisexual, and other men who have sex with men (MSM)
- Transgender women and travestis
- Other sexual and gender minorities (SGM)
- Cisgender women in situations of social or economic vulnerability
- Sex workers
- Individuals seeking HIV testing and/or pre-exposure prophylaxis (PrEP)
- HIV-negative at screening
- Willing and interested in initiating PrEP
- Eligible for PrEP according to Brazilian national guidelines
- Positive HIV test result at screening or during study participation
- Individuals not eligible for PrEP according to Brazilian national guidelines
The study team makes the final eligibility decision.
Where it's taking place
- Nova Iguaçu, Rio de Janeiro, Brazil
- Rio de Janeiro, Rio de Janeiro, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 15 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nova Iguaçu, Rio de Janeiro, Brazil; Rio de Janeiro, Rio de Janeiro, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.